J
James E. Herndon
Researcher at Duke University
Publications - 514
Citations - 46252
James E. Herndon is an academic researcher from Duke University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 107, co-authored 498 publications receiving 42578 citations. Previous affiliations of James E. Herndon include Harvard University & State University of New York Upstate Medical University.
Papers
More filters
Journal ArticleDOI
IDH1 and IDH2 Mutations in Gliomas
Hai Yan,D. Williams Parsons,Genglin Jin,Roger E. McLendon,B.K. Ahmed Rasheed,Weishi Yuan,Ivan Kos,Ines Batinic-Haberle,Siân Jones,Gregory J. Riggins,Henry S. Friedman,Allan H. Friedman,David A. Reardon,James E. Herndon,Kenneth W. Kinzler,Victor E. Velculescu,Bert Vogelstein,Darell D. Bigner +17 more
TL;DR: Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
Journal ArticleDOI
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh,Annick Desjardins,James E. Herndon,Jennifer Marcello,David A. Reardon,Jennifer A. Quinn,Jeremy N. Rich,Sith Sathornsumetee,Sridharan Gururangan,John H. Sampson,Melissa Wagner,Leighann Bailey,Darell D. Bigner,Allan H. Friedman,Henry S. Friedman +14 more
TL;DR: Bvacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
Journal ArticleDOI
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
James J. Vredenburgh,Annick Desjardins,James E. Herndon,Jeannette M. Dowell,David A. Reardon,Jennifer A. Quinn,Jeremy N. Rich,Sith Sathornsumetee,Sridharan Gururangan,Melissa Wagner,Darell D. Bigner,Allan H. Friedman,Henry S. Friedman +12 more
TL;DR: The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity and no central nervous system hemorrhages occurred.
Journal ArticleDOI
Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial
TL;DR: Long-term follow-up confirms that patients with stage III NSCLC who receive 5 weeks of chemotherapy with cisplatin and vinblastine before radiation therapy have a 4.1-month increase in median survival.
Journal ArticleDOI
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Gary M. Strauss,James E. Herndon,Michael A. Maddaus,David W. Johnstone,Elizabeth Johnson,David H. Harpole,Heidi H. Gillenwater,Dorothy Watson,David J. Sugarbaker,Richard L. Schilsky,Everett E. Vokes,Mark R. Green +11 more
TL;DR: A statistically significant survival advantage for patients who had tumors > or = 4 cm supports consideration of adjuvant paclitaxel/carboplatin for stage IB patients who have large tumors, and CALGB 9633 was underpowered to detect small but clinically meaningful improvements.